Study of Lutikizumab Injections in Adults with Moderate to Severe Hidradenitis Suppurativa or Atopic Dermatitis

What this Trial Is About

Researchers are evaluating molecular changes in adults with moderate to severe hidradenitis suppurativa HS or moderate to severe atopic dermatitis AD. This study includes two sub-studies, one for HS and one for AD, focusing on these chronic inflammatory skin diseases that cause painful skin lesions. The investigational drug lutikizumab ABT-981 is being studied to understand its effects on these conditions. Participants with HS or AD will receive subcutaneous injections of lutikizumab during a treatment period lasting up to 15 weeks for HS and 14 weeks for AD, followed by a 70-day follow-up. HS participants who show benefit at week 16 may enter a long-term extension to continue treatment for up to 140 weeks with weekly doses, plus another 70-day follow-up. Different participant groups include those new to biologic treatments and those with prior inadequate responses to certain therapies. Throughout the study, participants will attend regular visits at hospital or clinic sites for medical assessments, blood tests, and biomarker collection. Researchers will monitor adverse events up to approximately 30 weeks. The total study duration for each sub-study may last up to 30 weeks, with some participants potentially continuing in the long-term extension phase. The study aims to carefully assess treatment impact and safety in this adult population.

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab